You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 11, November 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Trial of Single-Dose Intravenous Gamma Globulin in Acute Kawasaki Disease

Preliminary Report

Mary Allen Engle, MD; Nunzia S. Fatica, MD; James B. Bussel, MD; John E. O'Loughlin, MD; Michael S. Snyder, MD; Martin L. Lesser, PhD

Am J Dis Child. 1989;143(11):1300-1304.


Abstract

• Gamma globulin administered in a single dose of 1 g/kg of body weight intravenously caused prompt clinical improvement in 27 of 32 consecutive children with Kawasaki disease treated by the 12th day of illness. Response was equally good for the 20 children treated in the first week and the 12 treated in the second week. Fever and clinical signs abated within the first day after treatment, the mean white blood cell count normalized by 48 hours, and the sedimentation rate continued to be elevated for about 2 weeks, while the platelet count rose during the first 2 weeks after treatment and returned to normal approximately 1 month after treatment. Five children with incomplete relief needed more than the single dose before resolution of signs and symptoms occurred. Coronary aneurysms in 2 patients before treatment regressed by 2 weeks. No patient developed coronary aneurysms. No child had sequelae of Kawasaki disease at a follow-up of 2 to 31 months. We believe that although this was a one-arm, uncontrolled pilot study, the results suggest that this protocol provides a safe, flexible, and effective treatment for acute Kawasaki disease.

(AJDC. 1989;143:1300-1304)



Author Affiliations

From the Divisions of Cardiology (Drs Engle, Fatica, O'Loughlin, and Snyder) and Hematology-Oncology (Dr Bussel), the Department of Pediatrics, and the Department of Public Health (Dr Lesser), The New York Hospital, Cornell University Medical College, New York; and the Division of Biostatistics, North Shore University Hospital, Manhasset, NY (Dr Lesser).


Footnotes

Accepted for publication May 10, 1989.

Read before the Northeast Pediatric Cardiology Society, Rye, NY, September 17, 1988, and the Third International Kawasaki Disease Symposium, Tokyo, Japan, December 1, 1988.

Reprint requests to The New York Hospital, Cornell Medical Center, 525 E 68th St, New York, NY 10021 (Dr Engle).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Kawasaki disease
Newburger and Burns
Vasc Med 1999;4:187-202.
ABSTRACT  

Kawasaki Disease: The More We Know, the Less We Know for Sure
Murphy
CLIN PEDIATR 1993;32:51-52.
 

SINGLE-DOSE GAMMA GLOBULIN IS EFFECTIVE IN KAWASAKI DISEASE
JWatch General 1989;1989:5-5.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.